A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer

Shi, Ji-Feng; Sun, Mengge; Li, Xiuying; Zhao, Yao; Ju, Rui-Jun; Mu, Li-Min; Yan, Yan; Li, Xuetao; Zeng, Fan; Lü, Wan-Liang

doi:10.1166/jbn.2015.2075

Cited by 37 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a preclinical level, the encapsulation of antiangiogenic drugs, such as sunitinib and sorafenib, has been attempted, in order to increase their activity. Sunitinib liposomes were tested, in combination with liposomal irinotecan against a PC12 neuroendocrine tumour [ 197 ] and in combination with vinorelbine liposomes, for the treatment of invasive breast cancer [ 198 ]. Sorafenib was co-encapsulated in liposomes with photocyanine [ 199 ], gadolinium [ 200 ], and siRNA [ 201 ].…”

Section: Future Directionsmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

Tumours are complex systems of genetically diverse malignant cells that proliferate in the presence of a heterogeneous microenvironment consisting of host derived microvasculature, stromal, and immune cells. The components of the tumour microenvironment (TME) communicate with each other and with cancer cells, to regulate cellular processes that can inhibit, as well as enhance, tumour growth. Therapeutic strategies have been developed to modulate the TME and cancer-associated immune response. However, modulating compounds are often insoluble (aqueous solubility of less than 1 mg/mL) and have suboptimal pharmacokinetics that prevent therapeutically relevant drug concentrations from reaching the appropriate sites within the tumour. Nanomedicines and, in particular, liposomal formulations of relevant drug candidates, define clinically meaningful drug delivery systems that have the potential to ensure that the right drug candidate is delivered to the right area within tumours at the right time. Following encapsulation in liposomes, drug candidates often display extended plasma half-lives, higher plasma concentrations and may accumulate directly in the tumour tissue. Liposomes can normalise the tumour blood vessel structure and enhance the immunogenicity of tumour cell death; relatively unrecognised impacts associated with using liposomal formulations. This review describes liposomal formulations that affect components of the TME. A focus is placed on formulations which are approved for use in the clinic. The concept of tumour immunogenicity, and how liposomes may enhance radiation and chemotherapy-induced immunogenic cell death (ICD), is discussed. Liposomes are currently an indispensable tool in the treatment of cancer, and their contribution to cancer therapy may gain even further importance by incorporating modulators of the TME and the cancer-associated immune response.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Vinorelbine is an anti-mitotic chemotherapy drug and has been used to treat some types of cancers, including breast cancer, non-small cell lung cancer and brain glioma [ 27 ]. The agent is the first semi-synthetic vinca alkaloid and the antitumor activity is due to inhibition of mitosis through interaction with tubulin [ 28 , 29 ]. Tetrandrine (TET) is a bis-benzylisoquinoline alkaloid, and it has been used as a calcium channel blocker.…”

Section: Introductionmentioning

confidence: 99%

Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells

Tang²,

Jiang

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

Malignant brain glioma is the most lethal and aggressive type of cancer. Surgery and radiotherapy cannot eliminate all glioma stem cells (GSCs) and blood–brain barrier (BBB) restricts the movement of antitumor drugs from blood to brain, thus leading to the poor prognosis with high recurrence rate. In the present study, the targeting conjugates of cholesterol polyethylene glycol polyethylenimine (CHOL-PEG2000-PEI) and D-a-tocopheryl polyethylene glycol 1000 succinate vapreotide (TPGS1000-VAP) were newly synthesized for transporting drugs across the BBB and targeting glioma cells and GSCs. The multifunctional targeting vinorelbine plus tetrandrine liposomes were constructed by modifying the targeting conjugates. The studies were undertaken on BBB model, glioma cells, GSCs, and glioma-bearing mice. In vitro results showed that multifunctional targeting drugs-loaded liposomes with suitable physicochemical property could enhance the transport drugs across the BBB, increase the intracellular uptake, inhibit glioma cells and GSCs, penetrate and destruct the GSCs spheroids, and induce apoptosis via activating related apoptotic proteins. In vivo results demonstrated that multifunctional targeting drugs-loaded liposomes could significantly accumulate into brain tumor location, show the specificity to tumor sites, and result in a robust overall antitumor efficacy in glioma-bearing mice. These data suggested that the multifunctional targeting vinorelbine plus tetrandrine liposomes could offer a promising strategy for treating brain glioma.

show abstract

“…44 The few examples of sunitinib liposomes were developed in combination with a cytotoxic drug to combine the antitumor and antiangiogenic activity; sunitinib was co-loaded with irinotecan in the same untargeted liposome, 45 or, more recently, sunitinib-loaded liposomes and vironelbine liposomes were co-administered to treat invasive breast cancer. 46 To best of our knowledge, however, this is the first example of targeted RGD-liposomes loaded with sunitinib.…”

Section: Discussionmentioning

confidence: 89%

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools

Bianchini

Santis

Portioli

et al. 2019

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

We report here the preparation, physico-chemical characterization, and biological evaluation of a new liposome formulation as a tool for tumor angiogenesis inhibition. Liposomes are loaded with sunitinib, a tyrosine kinase inhibitor, and decorated with cyclo-aminoprolineRGD units (cAmpRGD), efficient and selective ligands for integrin α V β 3 . The RGD units play multiple roles since they target the nanovehicles at the integrin α V β 3 -overexpressing cells (e.g. activated endothelial cells), favor their active cell internalization, providing drug accumulation in the cytoplasm, and likely take part in the angiogenesis inhibition by interfering in the α V β 3 -VEGFR2 cross-talk. Both in vitro and in vivo studies show a better efficacy of this integrated antiangiogenic tool with respect to the free sunitinib and untargeted sunitinib-loaded liposomes. This system could allow a lower administration of the drug and, by increasing the vector specificity, reduce side-effects in a prolonged antiangiogenic therapy.

show abstract

A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer

Cited by 37 publications

References 0 publications

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools

Contact Info

Product

Resources

About